<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00727597</url>
  </required_header>
  <id_info>
    <org_study_id>COL 110408</org_study_id>
    <nct_id>NCT00727597</nct_id>
  </id_info>
  <brief_title>A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT</brief_title>
  <acronym>SUPPoRT</acronym>
  <official_title>A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hope of this study is to gather data and information about the tolerability and
      effectiveness of Lexiva versus Sustiva in patients who have have been generally
      underrepresented in clinical trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to gain tolerability and efficacy data for Norvir-boosted
      Lexiva versus Sustiva, both used in combination with Epzicom, as components of a first-line,
      once daily regimen for the treatment of HIV-1 infection in a patient population that is
      underrepresented in US clinical research.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Needing to Switch Comparator Drugs (FPV/r or EFV)</measure>
    <time_frame>96 weeks</time_frame>
    <description>Subjects were randomized and initiated treatment on one of the antiretroviral arms(FPV/r or EFV) at study Entry visit. Subjects would be switched for the follwing reasons:
To resolve a Grade 3 or 4 Adverse Event
The subject experienced a virologic failure (as defined in section 3.6.2)
The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue
The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Developing Any Treatment-related Grade 3-4 Adverse Events</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Human Immunodeficiency Virus Infections</condition>
  <arm_group>
    <arm_group_label>Arm A : Boosted Lexiva plus Epzicom</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Efavirenz plus Epzicom</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz 600mg</intervention_name>
    <description>QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)
The intervention may be switched for the following reasons:
To resolve a Grade 3 or 4 Adverse Event
The subject experienced a virologic failure (as defined in section 3.6.2)
The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue
The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)</description>
    <arm_group_label>Arm B: Efavirenz plus Epzicom</arm_group_label>
    <other_name>Efavirenz(Sustiva)600 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Boosted Lexiva</intervention_name>
    <description>Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)
The intervention may be switched for the following reasons:
To resolve a Grade 3 or 4 Adverse Event
The subject experienced a virologic failure (as defined in section 3.6.2)
The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue
The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)</description>
    <arm_group_label>Arm A : Boosted Lexiva plus Epzicom</arm_group_label>
    <other_name>Fosamprenavir(Lexiva)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Screening plasma HIV-1 RNA viral load &gt;5000 copies/mL Self-identification as having any
        non-White/Caucasian European geographic ancestry (i.e., an individual is eligible if she/he
        does not have any White/Caucasian European ancestry; OR an individual is eligible if she/he
        indicates a mix of White/Caucasian European ancestry AND one or more other geographic
        ancestries); Antiretroviral-naïve (no treatment with any antiretroviral drug in the 28 days
        prior to study entry and ≤14 days of treatment ever with any antiretroviral drug) Negative
        test for the HLA-B*5701 allele Ability and willingness to give written informed consent

        Either gender is eligible, but enrollment of at least two female subjects to every one male
        subject is strongly encouraged. A female subject is eligible to participate in the study if
        she is of:

          1. Non-childbearing potential or,

          2. Childbearing potential with a negative pregnancy test at screen and agrees to use one
             of the following methods of contraception:

        i. Agreement for complete abstinence from intercourse from 2 weeks prior to administration
        of investigational products, throughout the study, and for 2 weeks after discontinuation of
        all study medications; ii. Double barrier contraception (male condom/spermicide, male
        condom/diaphragm, diaphragm/spermicide); iii. Any intrauterine device (IUD) with published
        data showing that the expected failure rate is less than 1% per year (not all IUDs meet
        this criterion); iv. Any other method with published data showing that the lowest expected
        failure rate for the method is less than 1% per year. v. Sterilization (female subject or
        male partner of female subject)

        Exclusion Criteria:

        Screening HIV-1 genotype indicating the presence of any of the following mutations in the
        reverse transcriptase (RT) region: K65R, L74V, K103N, Y115F, Y181C/I, Y188C/L/H or G190S/A,
        or a combination of two or more thymidine analog mutations (M41L, D67N, K70R, K219Q or E)
        that include changes at either L210 or T215, associated with resistance to abacavir,
        lamivudine, or efavirenz; OR within the protease region, detection of any of the following
        mutations associated with resistance to fosamprenavir or ritonavir: I50V, I54L/M, I84V, or
        the combination of the two mutations V32I+I147V Positive for Hepatitis B surface antigen
        (HBsAg+)

        Requirement for active treatment for hepatitis C virus infection, as indicated by both a
        positive Hepatitis C Virus serology AND either:

          1. Decompensated liver disease, or

          2. Aspartate aminotransferase (AST) &gt;3X the upper limit of normal (ULN), or

          3. Alanine aminotransferase (ALT) &gt;3X the ULN Currently pregnant, intending to become
             pregnant during the study period, or breast-feeding Use of immunomodulators (e.g.,
             interleukins, interferons, cyclosporine), any vaccinations, systemic cytotoxic
             chemotherapy, or investigational therapy within 28 days prior to study entry. Chronic
             treatment with prednisone at a daily dose of 10 mg or less is permitted. Acute
             treatment (less than 21 days) with larger doses of corticosteroids for acute therapy
             is permitted.

        Active or suspected drug or alcohol use or dependence that, in the opinion of the site
        investigator, would interfere with adherence to study requirements Judged by the
        investigator to be at significant risk of failing to comply with the provisions of the
        protocol as to cause harm to self or seriously interfere with the validity of the study
        results Active or acute Centers for Disease Control Clinical Category C event at screening.
        (Note: Treatment for the acute event must have been completed at least 28 days prior to
        screening.) Clinically relevant pancreatitis or clinically relevant hepatitis at screening
        Hgb&lt;8g/dl, platelet count &lt;50,000/mm3, calculated creatinine clearance &lt;50ml/min via
        Cockroft-Gault equation, or AST or ALT &gt; 5X the ULN Any Grade 4 laboratory abnormality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Princy Kumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2008</study_first_submitted>
  <study_first_submitted_qc>August 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2008</study_first_posted>
  <results_first_submitted>August 28, 2012</results_first_submitted>
  <results_first_submitted_qc>June 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2013</results_first_posted>
  <last_update_submitted>June 28, 2013</last_update_submitted>
  <last_update_submitted_qc>June 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Georgetown University</investigator_affiliation>
    <investigator_full_name>Princy Kumar, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Fosamprenavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients ≥18 years of age who were ART-naïve (≤14 days of treatment with any ART agent), HLA-B*5701-negative, and had a screening HIV-1 RNA &gt;5000 copies/mL. Patients were required to be of minority race or ethnicity; white, non-Hispanic patients were not eligible for this study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Once Daily (QD) Regimen of Lexiva</title>
          <description>Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg).</description>
        </group>
        <group group_id="P2">
          <title>QD Regimen of Sustiva</title>
          <description>QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Once Daily (QD) Regimen of Lexiva</title>
          <description>Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg).</description>
        </group>
        <group group_id="B2">
          <title>QD Regimen of Sustiva</title>
          <description>QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" spread="2"/>
                    <measurement group_id="B2" value="34" spread="2"/>
                    <measurement group_id="B3" value="34" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Needing to Switch Comparator Drugs (FPV/r or EFV)</title>
        <description>Subjects were randomized and initiated treatment on one of the antiretroviral arms(FPV/r or EFV) at study Entry visit. Subjects would be switched for the follwing reasons:
To resolve a Grade 3 or 4 Adverse Event
The subject experienced a virologic failure (as defined in section 3.6.2)
The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue
The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)</description>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Once Daily (QD) Regimen of Lexiva</title>
            <description>Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg).</description>
          </group>
          <group group_id="O2">
            <title>QD Regimen of Sustiva</title>
            <description>QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Needing to Switch Comparator Drugs (FPV/r or EFV)</title>
          <description>Subjects were randomized and initiated treatment on one of the antiretroviral arms(FPV/r or EFV) at study Entry visit. Subjects would be switched for the follwing reasons:
To resolve a Grade 3 or 4 Adverse Event
The subject experienced a virologic failure (as defined in section 3.6.2)
The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue
The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Developing Any Treatment-related Grade 3-4 Adverse Events</title>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Once Daily (QD) Regimen of Lexiva</title>
            <description>Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg).</description>
          </group>
          <group group_id="O2">
            <title>QD Regimen of Sustiva</title>
            <description>QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Developing Any Treatment-related Grade 3-4 Adverse Events</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Once Daily (QD) Regimen of Lexiva</title>
          <description>Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg).</description>
        </group>
        <group group_id="E2">
          <title>QD Regimen of Sustiva</title>
          <description>QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Suspected Drug Hypersensitivity to ABC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>cholesterol, total neutrophils, creatine kinase, and triglycerides</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Princy Kumar</name_or_title>
      <organization>Georegtown University</organization>
      <phone>2024440086</phone>
      <email>kumarp@georgetown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

